Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies
Affiliation
Department of Gastroenterology/Endocrinology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, GermanyIssue Date
2018
Metadata
Show full item recordCitation
H�rsch D, Garcia-Carbonero R, Valle JW, Perros P, Welin S, Keeber L, et al. 1314P Efficacy and safety of telotristat ethyl (TE) in combination with lanreotide (LAN) in patients with a neuroendocrine tumour and carcinoid syndrome (CS) diarrhoea (CSD): Meta-analysis of phase III double-blind placebo (PBO)-controlled TELESTAR and TELECAST studies. Annals of Oncology. 2018;29(suppl_8).Journal
Annals of OncologyDOI
10.1093/annonc/mdy293.007PubMed ID
No PMIDAdditional Links
https://dx.doi.org/10.1093/annonc/mdy293.007Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy293.007